Cassandra Pardini, PharmD

According to the findings of a recent review, the Food and Drug Administration rarely disagrees with recommendations made by its advisory committees.

A recently published report describes the case of a 24-year-old male patient who experienced a 6-year-long continuous headache that was resistant to over 20 different medical treatments but was successfully treated with venlafaxine.

A team of investigators from both Brigham and Women’s Hospital and the Massachusetts Institute of Technology analyzed data on thousands of inactive ingredients in approved medications to further characterize them and enhance our knowledge of their safety.

According to the results of a recent review, there is “insufficient” evidence to conclude that either nutmeg or St John’s wort are effective in helping treat pain in neuropathic conditions.

According to the results of a recently published study, FDANxSpray, the FDA-approved Narcan device for nasal administration, was found to yield higher plasma concentrations of naloxone compared to other devices used to treat opioid overdoses.

Although the quality of evidence is low due to variable study designs, botulinum toxin may be beneficial in the treatment of chronic tension-type headaches for specific patients with clear treatment goals.

In infants with neonatal abstinence syndrome, sublingual buprenorphine reduced the duration of treatment and decreased the length of hospital stay.

In patients with tophaceous gout, combination therapy of lesinurad plus febuxostat is more effective at reducing serum urate levels than febuxostat monotherapy.

A recent article outlined a 10-step program to assist clinicians in diagnosing and treating chronic daily headache.